A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)

This study is currently recruiting participants.
Verified October 2012 by Merck KGaA
Merck Ltd.
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
First received: August 12, 2011
Last updated: October 3, 2012
Last verified: October 2012

This prospective study will collect safety information from more than 600 patients treated with Pergoveris®.

During the Post-Marketing Surveillance (PMS) period, data about the patient´s background, patient's medical history, Pergoveris® indication, prior infertility medication, Pergoveris® treatment status, concomitant drugs, all adverse events (regardless of the causal relationship to Pergoveris®) and efficacy (follicular growth and clinical pregnancy) will be collected for study purposes.

The post marketing surveillance is based on all cases treated with Pergoveris®.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)

Resource links provided by NLM:

Further study details as provided by Merck KGaA:

Primary Outcome Measures:
  • Frequency and severity of all adverse events regardless of the causal relationship to Pergoveris® [ Time Frame: 30 month ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Clinical pregnancy [ Time Frame: 30 month ] [ Designated as safety issue: No ]
  • Percentage of patients with more than one follicle greater than 17mm on day of human chorionic gonadotrophin (HCG) administration [ Time Frame: 30 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 600
Study Start Date: August 2011
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Infertile patients


Inclusion Criteria:

  • Patients, who are eligible for Pergoveris® treatment according to the indication in the national label of Pergoveris®. The national label approved by Korea Food & Drug Administration is "Pergoveris® in association with a follicle stimulating hormone(FSH) preparation is recommended for the stimulation of follicular development in women with severe Luteinizing Hormone (LH) and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L"

Exclusion Criteria:

  • According to national label
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01416987

Contact: Merck KGaA Communication Center +49-6151-75-5200 service@merck.de

Korea, Republic of
Merck Serono Research Site Recruiting
Seoul, Korea, Republic of
Sponsors and Collaborators
Merck KGaA
Merck Ltd.
Study Director: Medical Responsible Merck Ltd.
  More Information

No publications provided

Responsible Party: Merck KGaA
ClinicalTrials.gov Identifier: NCT01416987     History of Changes
Other Study ID Numbers: EMR200061-507
Study First Received: August 12, 2011
Last Updated: October 3, 2012
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Follicle Stimulating Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 21, 2014